Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression

We have characterized expression of the familial breast and ovarian cancer gene, BRCA1, in cases of non–hereditary (sporadic) breast cancer and analyzed the effect of antisense inhibition of BRCA1 on the proliferative rate of mammary epithelial cells. BRCA1 mRNA levels are markedly decreased during the transition from carcinoma in situ to invasive cancer. Experimental inhibition of BRCA1 expression with antisense oligonucleotides produced accelerated growth of normal and malignant mammary cells, but had no effect on non–mammary epithelial cells. These studies suggest that BRCA1 may normally serve as a negative regulator of mammary epithelial cell growth whose function is compromised in breast cancer either by direct mutation or alterations in gene expression.

[1]  A. Nienhuis,et al.  An oligomer complementary to c-myc mRNA inhibits proliferation of HL-60 promyelocytic cells and induces differentiation , 1988, Molecular and cellular biology.

[2]  T. Akiyama,et al.  :A long term follow-up study , 1982 .

[3]  H. Soule,et al.  Estrogen responsive proliferation of clonal human breast carcinoma cells in athymic mice. , 1980, Cancer letters.

[4]  D. Page,et al.  Identification of genes expressed in premalignant breast disease by microscopy-directed cloning. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[5]  A. Whittemore,et al.  An evaluation of genetic heterogeneity in 145 breast-ovarian cancer families. Breast Cancer Linkage Consortium. , 1995, American journal of human genetics.

[6]  H. Nevanlinna,et al.  Evidence for involvement of BRCA1 in sporadic breast carcinomas. , 1994, Cancer research.

[7]  Francis S. Collins,et al.  Mutations in the BRCA1 gene in families with early-onset breast and ovarian cancer , 1994, Nature Genetics.

[8]  R. Bast,et al.  A deletion unit on chromosome 17q in epithelial ovarian tumors distal to the familial breast/ovarian cancer locus. , 1993, Cancer research.

[9]  Y. Nakamura,et al.  Detailed deletion mapping of chromosome 17q in ovarian and breast cancers: 2-cM region on 17q21.3 often and commonly deleted in tumors. , 1993, Cancer research.

[10]  W. Dupont,et al.  Intraductal carcinoma of the breast: Follow‐up after biopsy only , 1982, Cancer.

[11]  D. Page,et al.  Pathology and heredity of breast cancer in younger women. , 1994, Journal of the National Cancer Institute. Monographs.

[12]  M. Chalfie,et al.  Cooperative interactions between the Caenorhabditis elegans homeoproteins UNC-86 and MEC-3. , 1993, Science.

[13]  P. Rosen,et al.  Intraductal carcinoma. Long-term follow-up after treatment by biopsy alone. , 1978 .

[14]  J. Rommens,et al.  Common origins of BRCA1 mutations in Canadian breast and ovarian cancer families , 1994, Nature Genetics.

[15]  Steven E. Bayer,et al.  A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. , 1994, Science.

[16]  M. King,et al.  Linkage of early-onset familial breast cancer to chromosome 17q21. , 1990, Science.

[17]  David L. Page,et al.  Atypical hyperplastic lesions of the female breast. A long‐term follow‐up study , 1985, Cancer.

[18]  M. Scott,et al.  Homeotic genes regulate the spatial expression of putative growth factors in the visceral mesoderm of Drosophila embryos. , 1990, Development.

[19]  S. Neuhausen,et al.  Loss of heterozygosity in familial tumors from three BRCA1-linked kindreds. , 1994, Cancer Research.

[20]  Patrick Dowd,et al.  Confirmation of BRCA1 by analysis of germline mutations linked to breast and ovarian cancer in ten families , 1994, Nature Genetics.

[21]  F. Collins,et al.  Somatic mutations in the BRCA1 gene in sporadic ovarian tumours , 1995, Nature Genetics.

[22]  W. Dupont,et al.  Anatomic markers of human premalignancy and risk of breast cancer , 1990, Cancer.